J.V. Koomen, MSc
Telephone:
E-mail:
j.v.koomen umcg.nl
Research
Publications
Exposure-response relationships of dapagliflozin on cardiorenal risk markers and adverse events: A pooled analysis of 13 phase II/III trials
Koomen, J. V., Stevens, J. & Heerspink, H. J. L., 10-May-2020, In : British Journal of Clinical Pharmacology. 12 p.Research output: Contribution to journal › Article › Academic › peer-review
Exposure-response relationships for the sodium-glucose co-transporter-2 inhibitor dapagliflozin with regard to renal risk markers
Kroonen, M. Y. A. M., Koomen, J. V., Petrykiv, S. I., Laverman, G. D., Heerspink, H. J. L. & Stevens, J., 17-Feb-2020, In : Diabetes obesity & metabolism. 6 p.Research output: Contribution to journal › Article › Academic › peer-review
Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial
Koomen, J. V., Heerspink, H. J. L., Schrieks, I. C., Schwartz, G. G., Lincoff, A. M., Nicholls, S. J., Svensson, A., Wedel, H., Weichert, A., Grobbee, D. E. & Stevens, J., 1-Oct-2019, In : Diabetes obesity & metabolism. 9 p.Research output: Contribution to journal › Article › Academic › peer-review
Determining the optimal dose of atrasentan by evaluating the exposure-response relationships of albuminuria and bodyweight
Koomen, J. V., Stevens, J., Mostafa, N. M., Parving, H-H., de Zeeuw, D. & Heerspink, H. J. L., Aug-2018, In : Diabetes obesity & metabolism. 20, 8, p. 2019-2022 4 p.Research output: Contribution to journal › Article › Academic › peer-review
ID: 33450881